HealthCare Institute of New Jersey Statement on Vital Transformation Report on Price Controls
Trenton, July 29, 2022 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation: “A new report by the consultancy Vital Transformation on the impact that price control policies under discussion in Washington would have […]
HealthCare Institute of New Jersey Statement on Vital Transformation Report on Price Controls
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation.
HealthCare Institute of New Jersey Statement on Reconciliation Drug Pricing Legislation
Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation in a reconciliation package.
HealthCare Institute of New Jersey Announces New Board and Steering Committee Leadership
The HealthCare Institute of New Jersey (HINJ) has announced new officers of its Board of Trustees and the leadership of its Steering Committee, effective July 1.
Medical Technology is a Key Driver of New Jersey’s Life Sciences Engine
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer (Published in the print edition of the Asbury Park Press on Friday, May 13, 2022) New Jersey has long been globally recognized as the “Medicine Chest of the World” for its large and vibrant life sciences community. Our state proudly claims a broad swath […]
Pharmaceutical Rebates Benefit Insurers, PBMs More than Consumers — and That’s Wrong
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer Manufacturers frequently offer rebates that are passed through to consumers to reduce their purchase price of a product. For example, when buying a new car, the buyer gets the financial benefit of the manufacturer’s rebate rather than the dealer (middleman) keeping the rebate. […]
Statement by HINJ President and Chief Executive Officer Dean J. Paranicas in Response to Governor Murphy’s Drug Pricing Proposal
Trenton, February 14, 2022 ― “While we await the opportunity to review the actual bills that Governor Murphy proposed today, we look forward to working with the Administration and Legislature to broaden patient access to innovative medicines and therapies to improve patient outcomes and their quality of life. It is critical that this effort includes […]
Big Pharma Is to Blame for Drug Prices? Addressing Claims Shows That’s Not the Case
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer New Jersey’s research-based biopharmaceutical industry is constantly developing new cures and treatments that benefit New Jerseyans and patients worldwide. Over the past two years, we all have witnessed firsthand the industry’s remarkable and rapid response to identifying, treating and inoculating against COVID-19 with innovative […]
More Than Half of Spending on Brand Medicines Goes to PBMs, the Supply Chain, Other Entities – Not to Drug Companies
$350 billion goes to middlemen Trenton, January 11, 2022 ― An update to an important study demonstrates that pharmacy benefit managers (PBMs) and other middlemen in the pharmaceutical supply chain – not the drug companies – now receive more than half of the money spent on brand medicines. This represents money that instead could be […]
Help Scientists Combat the Next Global Health Crisis
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Christopher P. Molineaux, President and Chief Executive Officer of Life Sciences Pennsylvania December 26, 2021 – Nature is always finding fresh ways to attack human health. As America and the world combat the most serious global health crisis in a century, it’s […]